Skip to main content

Table 4 Univariate and multivariate analysis of factors with os using cox proportional hazards regression modeling

From: Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience

Variables Survival time, months P univariate P multivariate Odds ratio* (95 % CI)
Gender
 Male 24.8 ± 18.6    
 Female 29.4 ± 17.4 0.202   
Age, y
  ≤ 60 26.5 ± 19.4    
  > 60 25.6 ± 17.1 0.759   
Tumor marker
 Normal 26.7 ± 18.1    
 Abnormal 23.9 ± 19.2 0.479   
NLR
  ≤ 2.8 27.2 ± 18.4    
  > 2.8 24.1 ± 18.7 0.340   
Chemotherapy
 Yes 26.4 ± 18.6    
 N0 24.0 ± 16.9 0.576   
Types of surgery
 Endoscopic 66.0 ± 5.7    
 Open/Laparoscopic 41.7 ± 3.4 0.001 0.580 0.6 (0.1 ~ 4.2)
Depth of invasion
 T1/T2 34.2 ± 19.5    
 T3/T4 20.8 ± 15.5 <0.001 0.066 2.6 (0.9 ~ 7.2)
Lymph node metastasis
 N0 34.4 ± 20.4    
 N1 21.8 ± 15.6 <0.001 0.277 0.3 (0.0 ~ 2.5)
Number of positive LN
  ≤ 4 31.8 ± 20.5    
  > 4 19.9 ± 13.2 <0.001 0.795 0.9 (0.4 ~ 2.0)
Distant metastasis
 M0 27.2 ± 18.4    
 M1 12.9 ± 11.6 0.012 0.497 1.4 (0.5 ~ 4.1)
TNM stage
 I/II 35.0 ± 20.4    
 III/IV 21.5 ± 15.3 <0.001 0.248 3.9 (0.4 ~ 38.5)
Lesions diameter
  ≤ 4 cm 30.7 ± 19.2    
  > 4 cm 20.1 ± 15.3 0.001 0.730 1.1 (0.5 ~ 2.4)
Co-morbidity*
 Absent 27.9 ± 18.3    
 Present 19.7 ± 17.0 0.030 0.060 2.0 (0.9 ~ 4.1)
Surgical margin
 R0 28.6 ± 18.5    
 R1/R2 12.6 ± 9.3 <0.001 0.002 3.9 (1.6 ~ 9.1)
WHO classification
 NET G1/G2 35.6 ± 197    
 NET G3/MANEC 21.2 ± 15.5 <0.001 0.021 5.4 (1.3 ~ 22.9)
  1. OS overall survival, NLR Neutrophil-Lymphocyte Ratio, CI confidence interval, LN lymph node, Co-morbidity* including diabetes mellitus, chronic pulmonary disease, cardiovascular, chronic liver and renal disease; WHO World Health Organization, NET G1 neuroendocrine tumor G1, NET G2 neuroendocrine tumor G2, NEC G3 neuroendocrine carcinoma G3, MANEC mixed adenoneuroendocrine carcinoma